Cue Biopharma Inc (CUE)
1.08
+0.06
(+5.88%)
USD |
NASDAQ |
Jul 02, 16:00
1.08
0.00 (0.00%)
After-Hours: 20:00
Cue Biopharma Research and Development Expense (Annual): 40.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 40.80M |
| December 31, 2022 | 38.58M |
| December 31, 2021 | 41.35M |
| December 31, 2020 | 33.55M |
| December 31, 2019 | 27.49M |
| Date | Value |
|---|---|
| December 31, 2018 | 28.54M |
| December 31, 2017 | 18.90M |
| December 31, 2016 | 5.688M |
| December 31, 2015 | 1.504M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
27.49M
Minimum
2019
41.35M
Maximum
2021
36.35M
Average
38.58M
Median
2022
Research and Development Expense (Annual) Benchmarks
| XOMA Corp | 0.143M |
| Ardelyx Inc | 35.54M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |